At moments like these, the best I can do is pull out my best Keanu Reeves impersonation: Whoah.
Associated PressThe promise of an easy Fed sure has investors excited. The Dow Jones Industrial Average gained 421.28 points, or 2.4%, to 17.778.15 today, while the S&P 500 rose 2.4% to 4,748.40. Every stock in the Dow finished up today, with Microsoft (MSFT) and International Business Machines (IBM) and Goldman Sachs (GS) leading the way. Perhaps more frightening: By my count, just 21 S&P 500 stocks finished in the red today, as Oracle (ORCL) and First Solar (FSLR) led the benchmark higher.
It’s not just today’s gains, though they are impressive. Consider the two days the S&P 500 just had: It gained 4.5%, with the market up at least 2% on both days. The latter hasn’t happened since April 8, 2002–back when I was a 29-year old day trader not having to compete with those high-frequency guys.
Best Asian Companies To Invest In 2015: The Hain Celestial Group Inc.(HAIN)
The Hain Celestial Group, Inc., together with its subsidiaries, manufactures, markets, distributes, and sells natural and organic products in the United States and internationally. The company offers natural and organic grocery products, including non-dairy beverages and frozen desserts, infant and toddler food, flour and baking mixes, hot and cold cereals, pasta, condiments, cooking and culinary oils, granolas, granola bars, cereal bars, canned, aseptic and instant soups, yogurt, chilis, packaged grain, chocolate, nut butters, nutritional oils, juices, frozen desserts, cookies, crackers, gluten-free frozen entrees and bars, frozen pastas, and ethnic meals. It also provides snack products, such as potato and vegetable chips, organic tortilla style chips, whole grain chips, and popcorn; and specialty tea, including herbal, green, wellness, white, red, and chai teas. In addition, the company offers personal care products, including skin care, hair care, body care, oral care, deodorants, and baby care items, including acne treatment, body washes, and sunscreens. Further, it processes, markets, and distributes prepared foods, such as fresh sandwiches, appetizers, and full-plated meals for distribution to retailers, caterers, and food service providers; and develops, manufactures, markets, distributes, and sells a line of household cleaning products, including laundry detergent and fabric softener, and dish cleaners, as well as glass, bathroom, wood floor, and all purpose cleaners. The company sells its products to specialty and natural food distributors, as well as to supermarkets, natural food stores, mass-market and on-line retailers, drug store chains, food service channels, and club stores. The Hain Celestial Group, Inc. was founded in 1993 and is headquartered in Melville, New York.
Advisors' Opinion:- [By Rich Duprey]
Whole Foods Market (NASDAQ: WFM ) �may be the closest place investors can readily turn to, and it is leading the drive for mandatory labeling of GM products (though some complain its five-year timeline amounts to glacial foot-dragging). Tea maker Hain Celestial (NASDAQ: HAIN ) �is another, as it strives to maintain GMO-free blends.
5 Best Stocks To Invest In 2014: Gilead Sciences Inc.(GILD)
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 1987 and is headquartered in Fost er City, California.
Advisors' Opinion:- [By Sue Chang]
Gilead Sciences Inc. (GILD) reported blockbuster second-quarter results and posted strong sales numbers for its new hepatitis C drug Sovaldi. Gilead shares gained more than 1% in extended trading.
- [By David Williamson and Michael Douglass]
Big biotech�Gilead�(Nasdaq: GILD) has gone on a tremendous 200% two year run as its groundbreaking hepatitis-C cure Sovaldi is breaking all expectations with $2.3 billion in just its first quarter of availability.
- [By Jay Silverman]
Over the past year, including the end of this year, we've had new blockbuster drugs for hepatitis C, which is Gilead's (GILD) drug, and also for B-cell lymphomas, which is Pharmacyclics' (PCYC) drug. Those are looking to be two of the biggest drugs ever.
- [By Ben Levisohn]
Remember when biotech stocks like Gilead Sciences (GILD) and Celgene (CELG) were getting creamed and everyone was wondering if the biotech boom was finished? Yeah, neither do I.
We’d better refresh our memories, however. The iShares Nasdaq Biotechnology ETF (IBB) has rallied 20% since dropping 21% from the February 25 through April 11. And large-cap biotech stocks now trade at 16.3 times 2015 earnings versus the S&P 500′s 14.8 times. That, says Nomura’s M. Ian Somaiya and team makes beating earnings forecasts an imperative, who says “lackluster 1Q earnings have increased reliance on solid 2Q results to maintain momentum in the group.”
Somaiya points to Gilead Sciences, Alexion Pharmaceuticals (ALXN), Celgene and Incyte (INCY) as the biotech companies most likely to beat earnings:
For Gilead Sciences, we believe Sovaldi sales reach $3bn, almost 2x our $1.6bn and above the Street�� $2.6bn estimates, based on strength of prescription data. For Alexion Pharmaceuticals, we believe upside will come from a higher-than-expected rate of patient starts in ROW territories for PNH, a $1-2bn opportunity, and Europe for aHUS. For Celgene, we believe 2Q revenue estimates could be understated due to 1Q seasonality and inventory drawdowns, setting up for a potential beat in Revlimid, Pomalyst and Abraxane. For Incyte, we expect Jakafi sales to bounce back in 2Q, given inventories returned to the low end of the normal range, gross-to-net returns to the 9-10% guidance, and a 4.75% price increase on 1 April. In addition, data presentations at ASCO could have increased off-label usage in pancreatic cancer and PV.
Shares of Gilead Sciences have gained 1.4% to $89.96 at 1:26 p.m., Alexion Pharmaceuticals has risen 0.6% to $164.22, Incyte has advanced 1% to $51.34 and Celgene has fallen 0.8% to $84.46. The iShares Nasdaq Biotechnology ETF is up 0.6% at $258.33.
5 Best Stocks To Invest In 2014: Highway 50 Gold Corp (HWY)
Highway 50 Gold Corp. is an exploration-stage company. The Company is engaged principally in the acquisition and exploration of exploration and evaluation assets. The Company owns, or has the right to acquire an interest in, two projects located in Nevada (the Golden Brew Property and the Porter Canyon Project). Porter Canyon Project consists of 201 unpatented claims located in Lander County, Nevada that cover the projected north-eastern terminus of the Eastgate volcanic trough under pediment cover outboard of the Quito Mine. The Golden Brew claims (Golden Brew) consists of 153 claims prospective for Carlin-style gold mineralization. The gold mineralization at Golden Brew consists of a zone of gold bearing jasperoid measuring 2,500 feet long and up to 200 feet wide, hosted in thin bedded platey Cambrian-aged carbonates. Advisors' Opinion:- [By Ben Levisohn]
It wasn’t all good news, however. Healthways�(HWY) plunged 30% to $11.41, making it the S&P 1500′s biggest loser, while�Cameron International (CAM) fell 18% to $53.25, making it the S&P 500′s weakest stock. Both released disappointing earnings reports this week.
5 Best Stocks To Invest In 2014: ZELTIQ Aesthetics Inc (ZLTQ)
ZELTIQ Aesthetics, Inc. (ZELTIQ), incorporated on March 22, 2005, is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product is the CoolSculpting System that reduces stubborn fat bulges. The Company generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. As of March 31, 2011, it had an installed base of 346 and 475 CoolSculpting Systems worldwide and over 88,000 CoolSculpting procedures had been sold to its physician customers. The Company markets CoolSculpting to the dermatologists, plastic surgeons, and aesthetic specialists. As of March 31, 2011, ZELTIQ�� North American direct sales force consisted of 23 professionals, and over 88,000 CoolSculpting procedures were sold to ZELTIQ�� physician customers.
CoolSculpting System
ZELTIQ generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. Capital sales of ZELTIQ�� CoolSculpting System include the CoolSculpting control unit and its CoolSculpting vacuum applicators. ZELTIQ generates procedure fees through sales of CoolSculpting procedure packs, which include its consumable gelpads and liners and a disposable computer cartridge that it markets as the CoolCard. The CoolCard contains enabling software that permits its physician customer to perform a fixed number of CoolSculpting procedures.
The CoolSculpting control unit is the base of the CoolSculpting System. ZELTIQ�� CoolSculpting control unit also contains software that tracks and collects data about each procedure performed and any error messages that may be generated during the procedure. CoolSculpting System includes three CoolSculpting vacuum applicators. ZELTIQ�� CoolSculpting procedure packs facilitate the pay-per-procedu! re feature of its CoolSculpting System. Its CoolSculpting procedure packs include CoolCard and its consumable gelpads and liners.
Advisors' Opinion:- [By Garrett Cook]
Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from ZELTIQ Aesthetics (NASDAQ: ZLTQ) and Aegerion Pharmaceuticals (NASDAQ: AEGR).
- [By Sean Williams]
Zeltiq Aesthetics (NASDAQ: ZLTQ )
Last, but certainly not least, we have Zeltiq Aesthetics, which utilizes its proprietary medical devices for the selective reduction of fat in patients. Understandably, we're not talking about a pharmacological solution here or even a long-term one necessarily. This is more of an aesthetic solution in cases where diet and exercise aren't meeting the patients' goal, but it should be noted that people will pay top dollar to look healthier and thinner, so Zeltiq's target audience is actually very large. - [By John Udovich]
On Tuesday, small cap biotech stock Kythera Biopharmaceuticals Inc (NASDAQ: KYTH) surged around 25% after announcing that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints for the reduction of so-called double chins; but if investors missed out on that rally, small caps Zeltiq Aesthetics Inc (NASDAQ: ZLTQ), Solta Medical Inc (NASDAQ: SLTM) and Cynosure, Inc (NASDAQ: CYNO) each have a piece of the aesthetic market as well. In the case of Kythera Biopharmaceuticals, its ATX-101 can be injected to deal with double chins���meaning its less invasive than liposuction as the drug dissolves fat cells but leaves other tissue alone. JP Morgan has noted:
- [By Garrett Cook]
Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from ZELTIQ Aesthetics (NASDAQ: ZLTQ) and Aegerion Pharmaceuticals (NASDAQ: AEGR).
No comments:
Post a Comment